MedTrace Logo

Safety Study of MRI-guided Transurethral Ultrasound Ablation of Prostate Tissue to Treat Localized Prostate Cancer

NCT01686958 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-02-11

Study results available
· View outcomes & findings →

Summary

This study is to evaluate that the magnetic resonance imaging (MRI)-guided transurethral ultrasound therapy system is safe and feasible to ablate prostate tissue in men with localized prostate cancer.

Conditions

Interventions

DEVICE

MR-Guided Transurethral US Ablation of Prostate Tissue

The technology is developed to treat patients with organ confined prostate cancer. The therapeutic endpoint of this technology is thermal coagulation of prostate tissue.

Sponsors & Collaborators

  • Profound Medical Inc.

    lead OTHER

Principal Investigators

  • Joseph Chin, MD · London Health Science Center

  • James Relle, MD · William Beaumont Hospitals

  • Ryan Berglund, MD · The Cleveland Clinic

  • Heinz P Schlemmer, MD · German Cancer Research Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-13
Primary Completion
2015-03-23
Completion
2019-06-11

Countries

  • United States
  • Canada
  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01686958 on ClinicalTrials.gov